



PATIENT NAME : KUMARI SALONI	REF. DOCTOR	R: SELF
CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0028WF000247 PATIENT ID : KUMAF01019028 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status <u>Preliminary</u>	Results Biologi	ical Reference Interval Units

.....

HAEMATOLOGY - CBC

<u>(</u>			
MEDI WHEEL FULL BODY HEALTH CHECKUP BI	ELOW 40FEMALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : SPECTROPHOTOMETRY	12.5	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : ELECTRICAL IMPEDANCE	4.96 High	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : ELECTRICAL IMPEDANCE	8.50	4.0 - 10.0	thou/µL
PLATELET COUNT	181	150 - 410	thou/µL
METHOD : ELECTRICAL IMPEDANCE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER	38.7	36.0 - 46.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED/COULTER PRINCIPLE	78.0 Low	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	25.3 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.4	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED/COULTER PRINCIPLE	15.3 High	11.6 - 14.0	%
MENTZER INDEX METHOD : CALCULATED PARAMETER	15.7		
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED/COULTER PRINCIPLE	11.6 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			

NEUTROPHILS	51	40 - 80	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY LYMPHOCYTES	40	20 - 40	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY			

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Fmail : customercare.poida@srLin Email : customercare.noida@srl.in



View Report









PATIENT NAME : KUMARI SALONI	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS :C000138361	ACCESSION NO : 0028WF000247	AGE/SEX : 33 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : KUMAF01019028	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/06/2023 09:38:18
NEW DELHI 110030	ABHA NO :	REPORTED :12/06/2023 10:30:48
8800465156		

Test Report Status Results Biological Reference Interval Units **Preliminary** 8 2.0 - 10.0% MONOCYTES METHOD : VCS TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 % METHOD : VCS TECHNOLOGY/ MICROSCOPY 0 - 1 % BASOPHILS 0 METHOD : VCS TECHNOLOGY/ MICROSCOPY 4.30 2.0 - 7.0 thou/µL ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED PARAMETER 3.40 High thou/µL ABSOLUTE LYMPHOCYTE COUNT 1.0 - 3.0 METHOD : CALCULATED PARAMETER ABSOLUTE MONOCYTE COUNT 0.60 0.2 - 1.0 thou/µL METHOD : CALCULATED PARAMETER ABSOLUTE EOSINOPHIL COUNT 0.08 0.02 - 0.50 thou/µL METHOD : CALCULATED PARAMETER 0.00 Low 0.02 - 0.10 thou/µL ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED PARAMETER

METHOD : CALCULATED PARAMETER

NEUTROPHIL LYMPHOCYTE RATIO (NLR)

Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

1.3

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR <

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Report









PATIENT NAME : KUMARI SALONI	REF. DOCTOR :	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0028WF000247 PATIENT ID : KUMAF01019028 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

<u></u>	HAEMATOLOG	Y	
MEDI WHEEL FULL BODY HEALTH	CHECKUP BELOW 40FEMALE		
ERYTHROCYTE SEDIMENTATION	RATE (ESR),WHOLE		
E.S.R	8	0 - 20	mm
METHOD : MODIFIED WESTERGREN METHOD B	Y AUTOMATED ANALYSER		

Interpretation(s) ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Explorecyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Report



View Details







PATIENT NAME : KUMARI SALONI	REF. DOCTOR : 3	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI		AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status Preliminary	Results Biological	Reference Interval Units

Test Report Status **Preliminary**

Biological Reference Interval Units

IMMUNOHAEMATOLOGY			
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE			
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD			
ABO GROUP	TYPE B		
METHOD : COLUMN AGGLUTINATION TECHOLOGY			
RH TYPE	POSITIVE		
METHOD : COLUMN AGGLUTINATION TECHOLOGY			

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Details



Page 4 Of 23

View Report





PATIENT NAME : KUMARI SALONI	REF. DOC	CTOR : SELF
CODE/NAME & ADDRESS :C000138361	ACCESSION NO : 0028WF00024	AGE/SEX : 33 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : KUMAF01019028	8 DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/06/2023 09:38:18
NEW DELHI 110030	ABHA NO :	REPORTED :12/06/2023 10:30:48
8800465156		
Test Report Status <u>Preliminary</u>	Results Bio	logical Reference Interval Units
1		1
	BIOCHEMISTRY	
MEDI WHEEL FULL BODY HEALTH CHECKUP E		
MEDI WHEEL FULL BODY HEALTH CHECKUP E GLUCOSE FASTING,FLUORIDE PLASMA		j

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	5.3*	Non-diabetic Adult < 5.7 % Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)
METHOD : HPLC ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116.0 mg/dL

Comments

*GLYCOSYLATED HEMOGLOBIN A VARIANT HB PEAK IS NOTED IN THE HPLC GRAPH. SUGGEST: 1.HB ELECTROPHORESIS/HB VARIANT ANALYSIS FOR CONFIRMATION AND IDENTIFICATION OF THE HEMOGLOBIN VARIANT GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)	103	Non-Diabetes	mg/dL
		70 - 140	

METHOD : HEXOKINASE

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL

149

METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



mg/dL

< 200 Desirable

>/= 240 High

200 - 239 Borderline High









PATIENT NAME : KUMARI SALONI	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 00 PATIENT ID : KUN CLIENT PATIENT ID: ABHA NO :	MAF01019028 DRAWN : RECEIVED : 10/0	ears Female 6/2023 09:38:18 6/2023 10:30:48
Test Report Status <u>Preliminary</u>	Results	Biological Reference Inte	rval Units
TRIGLYCERIDES	66	< 150 Normal 150 - 199 Borderline Hig 200 - 499 High >/= 500 Very High	mg/dL h
METHOD : ENZYMATIC, END POINT HDL CHOLESTEROL	54	< 40 Low >/=60 High	mg/dL
METHOD : DIRECT MEASURE POLYMER-POLYANION CHOLESTEROL LDL	82	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL

NON HDL CHOLESTEROL	95	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	13.2	Desirable value : 10 - 35	mg/dL
CHOL/HDL RATIO	2.8 Low	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	1.5	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderat Risk >6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Report









PATIENT NAME : KUMARI SALONI	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS :C000138361	ACCESSION NO : 0028WF000247	AGE/SEX : 33 Years Female		
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KUMAF01019028	DRAWN :		
	CLIENT PATIENT ID:	RECEIVED : 10/06/2023 09:38:18		
NEW DELHI 110030	ABHA NO :	REPORTED :12/06/2023 10:30:48		
8800465156				
C	1	•		

Test Report Status Preliminary

Results

Biological Reference Interval Units

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk		major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk		betes with 1 major risk factor or no evidence of end organ	
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	actors	
1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females 3. Current Cigarette smoking or tobacco use		3. Current Cigarette smoking or tobacco use	
2. Family history of premature ASCVD 4. High blood pressure		4. High blood pressure	
5. Low HDL			
Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.			

Risk Group Consider Drug Therapy Treatment Goals LDL-C (mg/dl) Non-HDL (mg/dl) LDL-C (mg/dl) Non-HDL (mg/dl) < 80 (Optional goal Extreme Risk Group Category A <50 (Optional goal >OR = 50 >OR = 80< OR = 30) < OR = 60) <OR = 30 Extreme Risk Group Category B < OR = 60> 30 >60 <50 >OR= 50 >OR= 80 Very High Risk <80 High Risk <70 <100 >OR= 70 >OR=100

<130

<130

*After an adequate non-pharmacological intervention for at least 3 months.

<100

<100

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

>OR=100

>OR=130*

>OR=130

>OR=160

LIVER FUNCTION PROFILE, SERUM

	0.35	UPTO 1.2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE) BILIRUBIN, DIRECT	0.15	0.00 - 0.30	mg/dL
	0.15	0.00 - 0.30	mg/uL
METHOD : DIAZOTIZATION			
BILIRUBIN, INDIRECT	0.20	0.00 - 0.60	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.3	6.6 - 8.7	g/dL
METHOD : BIURET, SERUM BLANK, ENDPOINT			
ALBUMIN	4.5	3.97 - 4.94	g/dL
METHOD : BROMOCRESOL GREEN			

Moderate Risk

Low Risk

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in









0 - 32

0 - 31

5.00 - 15.00



U/L

U/L

MC-2261

PATIENT NAME: KUMARI SALONI	REF. DOCTOR : SELF				
CODE/NAME & ADDRESS : C000138361	ACCESSION NO	D: 0028WF000247	AGE/SEX	:33 Years	Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID	: KUMAF01019028	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIEN	T ID:	i	: 10/06/2023	
NEW DELHI 110030	ABHA NO	:	REPORTED	:12/06/2023	10:30:48
8800465156					
Test Report Status <u>Preliminary</u>	Results	Biological	Reference	e Interval l	Jnits
GLOBULIN	2.8	2.0 - 4.0 Neonates Pre Mature 0.29 - 1.0	e:	g/d	IL
METHOD : CALCULATED PARAMETER					
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.6	1.0 - 2.0		RA	ПО

METHOD : UV WITHOUT P5P ALKALINE PHOSPHATASE METHOD : PNPP, AMP BUFFER-IFCC GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE-IFCC LACTATE DEHYDROGENASE METHOD : L TO P, IFCC	82 14 150	35 - 105 5 - 36 135 - 214	U/L U/L U/L
BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN METHOD : UREASE - UV	8	6 - 20	mg/dL
CREATININE, SERUM CREATININE METHOD : ALKALINE PICRATE-KINETIC	0.74	0.50 - 0.90	mg/dL

10.81

18

16

BUN/CREAT RATIO

BUN/CREAT RATIO METHOD : CALCULATED PARAMETER

ASPARTATE AMINOTRANSFERASE(AST/SGOT)

ALANINE AMINOTRANSFERASE (ALT/SGPT)

METHOD: UV WITHOUT P5P

URIC ACID, SERUM

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in











PATIENT NAME : KUMARI SALO	NI	REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138			EX : 33 Years Female
ACROFEMI HEALTHCARE LTD (MED		KUMAF01019028 DRAW	
F-703, LADO SARAI, MEHRAULISO	UTH WEST		/ED :10/06/2023 09:38:18
	АВНА NO		TED :12/06/2023 10:30:48
NEW DELHI 110030 8800465156			12,00,2020 20:001:0
Test Report Status <u>Prelimina</u>	ary Results	Biological Refere	ence Interval Units
URIC ACID METHOD : URICASE, COLORIMETRIC	4.3	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.3	6.6 - 8.7	g/dL
METHOD : BIURET, SERUM BLANK, ENDPOINT			2
ALBUMIN, SERUM			
ALBUMIN	4.5	3.97 - 4.94	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN			
GLOBULIN	2.8	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SER	UM		
SODIUM, SERUM	135 Low	136 - 145	mmol/L
METHOD : ISE INDIRECT POTASSIUM, SERUM	4.22	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT	7.22	5.5 5.1	
CHLORIDE, SERUM METHOD : ISE INDIRECT	97 Low	98 - 107	mmol/L
Interpretation(s)			
Sodium	Potassium	Chloride	
Goel			Page 9 Of 23
Dr. Shyla Goel,M.B.B.S ,DCP Sr.Pathologist			View Details View Report
PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd B-22, Sector-62 Noida, 201301))	Pa	tient Ref. No. 775000003510799

Agilus Diagnostics Ltd (Formerly SF B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in





PATIENT NAME : KUMARI SALONI	REF. DOCTOR : SELF			
	ACCESSION NO : 0028WF000247	AGE/SEX : 33 Years Female		
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : KUMAF01019028	DRAWN :		
DELAI		RECEIVED : 10/06/2023 09:38:18		
NEW DELHI 110030	ABHA NO :	REPORTED :12/06/2023 10:30:48		
8800465156				
NEW DELHI 110030	ABHA NO :	REPORTED :12/06/2023 10:30:48		

Test Report Status Preliminary Results

Biological Reference Interval Units

Decreased in:CCF.cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake, prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia), alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide, carbamazepine, anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
depressants (55ki), antipsychotics.	diaretics.	hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in Debudration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
Increased in: Dehydration		
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration, overtreatment with
vomiting or diarrhea), diabetes	acidosis, dehydration,renal failure,	
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline, hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, or al contraceptives.	potassium- sparing diuretics, NSAIDs,	alkalosis, hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, androgens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency

diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

 Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Report









PATIENT NAME : KUMARI SALONI	REF. DOCTOR : SELF			
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KUMAF01019028 CLIENT PATIENT ID:	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48		
Test Report Status Preliminary	Results Biological	Reference Interval Units		

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

a) homozygous hemoglobinopathy. Proceeding is recommended for testing of hDATC. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin transferred Paral Chromatography is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give vellow its a velocities pignetic found in the and is a breakdown production in the calculations. Dim doin is exterice in which and envice neves may give obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain

and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic

syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Report









MC-2201						
PATIENT NAME : KU	MARI SALONI	RE	F. DOCTOR :	SELF		
CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156		ACCESSION NO : 0028WI PATIENT ID : KUMAFO: CLIENT PATIENT ID: ABHA NO :		DRAWN RECEIVED		Female 23 09:38:18 23 10:30:48
Test Report Status	Preliminary	Results	Biologica	l Referenc	e Interval	Units
	CLINI	CAL PATH - URINALYSIS				
MEDI WHEEL FULL B	ODY HEALTH CHECKUP BI	ELOW 40FEMALE				
PHYSICAL EXAMINA						
COLOR		PALE YELLOW				
METHOD : VISUAL APPEARANCE METHOD : VISUAL		SLIGHTLY HAZY				
CHEMICAL EXAMINA PH	TION, URINE	6.5	4.7 - 7.5			
METHOD : DOUBLE INDICATO SPECIFIC GRAVITY		<=1.005	1.003 - 1	.035		
PROTEIN METHOD : PROTEIN- ERROR	RETREATED POLYELECTROLYTES	NOT DETECTED	NOT DETE	ECTED		
GLUCOSE METHOD : OXIDASE-PEROXI	DASE REACTION	NOT DETECTED	NOT DETE	-		
	ACTION WITH NITROPRUSSIDE		NOT DETE			
BLOOD METHOD : PEROXIDASE-LIKE BILIRUBIN	E ACTIVITY OF HEMOGLOBIN	DETECTED (+)	NOT DETE NOT DETE	-		
METHOD : DIAZOTIZATION		NORMAL	NORMAL			
METHOD : MODIFIED EHRLIC		NOT DETECTED	NOT DETE	ECTED		
METHOD : CONVERTION OF I LEUKOCYTE ESTERAS METHOD : ESTERASE HYDRO	SE	NOT DETECTED	NOT DET	ECTED		
MICROSCOPIC EXAM	INATION, URINE					
RED BLOOD CELLS METHOD : MICROSCOPIC EX	AMINATION	2 - 3	NOT DETE	ECTED	/	HPF
PUS CELL (WBC'S)		2-3	0-5		/	HPF

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Fmail : customercare.poida@srLin Email : customercare.noida@srl.in











PATIENT NAME : KUMARI SALONI	REF. DOCTOR : S	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KUMAF01019028 CLIENT PATIENT ID:	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

METHOD : MICROSCOPIC EXAMINATION EPITHELIAL CELLS METHOD : MICROSCOPIC EXAMINATION	8-10	0-5	/HPF
CASTS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION CRYSTALS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED		
BACTERIA	DETECTED (++)	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION YEAST	NOT DETECTED	NOT DETECTED	
REMARKS			
	NOTE THAT GRADING OF B THE CULTURE IN CASE FOU	ON DONE ON CENTRIFUGED URII ACTERIA NEEDS TO BE CO RELAT JND SIGNIFICANT CLINICALLY. O EEN IN MICROSCOPY CAN BE A P	ED WITH CCASIONAL

SURROUNDING SKIN FLORA ALSO.

METHOD : MANUAL

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in

Page 13 Of 23

View Report









PATIENT NAME : KUMARI SALONI	REF. DOCTOR : S	SELF
	ACCESSION NO : 0028WF000247	AGE/SEX : 33 Years Female
	PATIENT ID : KUMAF01019028	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/06/2023 09:38:18
	ABHA NO :	REPORTED :12/06/2023 10:30:48
8800465156		

Test Report Status	Preliminary	Results	

Biological Reference Interval Units

Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Fmail : customercare.poida@srLin Email : customercare.noida@srl.in

Page 14 Of 23









PATIENT NAME : KUMARI SALONI	REF. DOCTOR :	SELF
	ACCESSION NO : 0028WF000247	AGE/SEX : 33 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KUMAF01019028 CLIENT PATIENT ID:	DRAWN : RECEIVED : 10/06/2023 09:38:18
NEW DELHI 110030	ABHA NO :	REPORTED :12/06/2023 10:30:48
8800465156		

Test Report Status Preliminary Results

Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE **PAPANICOLAOU SMEAR**

SPECIMEN TYPE

REPORTING SYSTEM SPECIMEN ADEQUACY MICROSCOPY **INTERPRETATION / RESULT**

Cytology number C-1711-23 Cervical cytological preparation 2 smears examined 2014 Bethesda system Smears are satisfactory for evaluation Endocervical cells/transformation zone component present Negative for intraepithelial lesion or malignancy

Comments

Pap smear cytology is a screening test. Corroboration of cytopathologic findings with colposcopic/local examination and ancillary findings is recommended.

Dr. Noopur Gupta Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Report









PATIENT NAME: KUMARI SALONI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WF000247 AGE/SEX :33 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : KUMAF01019028 DRAWN ÷ F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 10/06/2023 09:38:18 DELHI ABHA NO REPORTED :12/06/2023 10:30:48 : NEW DELHI 110030 8800465156 Test Report Sta Results Units

atus	Prelin	minaı	v
			_

Biological Reference Interval

	SPECIALISED CHEMISTRY - H	IORMONE	
MEDI WHEEL FULL BODY HEALTH CH	IECKUP BELOW 40FEMALE		
THYROID PANEL, SERUM			
T3 METHOD : ECLIA	140.6	80.00 - 200.00	ng/dL
T4 METHOD : ECLIA	6.74	5.10 - 14.10	µg/dL
TSH (ULTRASENSITIVE)	2.260	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	
METHOD : ECLIA			

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3 Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Report

111

3 U -View Details







PATIENT NAME : KUMARI SALONI	REF. DOCTOR : S	SELF
	ACCESSION NO : 0028WF000247	AGE/SEX : 33 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KUMAF01019028	DRAWN :
DELHI		RECEIVED : 10/06/2023 09:38:18
NEW DELHI 110030	ABHA NO :	REPORTED :12/06/2023 10:30:48
8800465156		
	1	1

Test Report Status	Preliminary	Results	Biological Reference Interval	Units

4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in

Page 17 Of 23

View Report







PATIENT NAME: KUMARI SALONI REF. DOCTOR : SELF CODE/NAME & ADDRESS :C000138361 ACCESSION NO : 0028WF000247 AGE/SEX : 33 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) DRAWN PATIENT ID : KUMAF01019028 : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 10/06/2023 09:38:18 DELHÍ ABHA NO REPORTED :12/06/2023 10:30:48 : NEW DELHI 110030 8800465156 **Test Report Status** Results **Biological Reference Interval** Units **Preliminary**

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

XRAY-CHEST	
»»	BOTH THE LUNG FIELDS ARE CLEAR
»»	BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR
»»	BOTH THE HILA ARE NORMAL
»»	CARDIAC AND AORTIC SHADOWS APPEAR NORMAL
»»	BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL
»»	VISUALIZED BONY THORAX IS NORMAL
IMPRESSION	NORMAL

TMT OR ECHO	RESULT PENDING
ECG	
ECG	WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY	NOT SIGNIFICANT
RELEVANT PAST HISTORY	H/O LOWER BACK PAINSINCE 1 MONTH.
RELEVANT PERSONAL HISTORY	MARRIED, NON VEGETARIAN.
RELEVANT FAMILY HISTORY	MOTHER-HIGH BLOOD PRESSURE.
OCCUPATIONAL HISTORY	NOT SIGNIFICANT
HISTORY OF MEDICATIONS	NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS	1.62	mts
WEIGHT IN KGS.	65	Kgs

Page 18 Of 23



View Details



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in



PATIENT NAME : KUMARI SALONI	REF. DOCTOR :	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0028WF000247 PATIENT ID : KUMAF01019028 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

BMI

25

BMI & Weight Status as follows/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER
THYROID GLAND	NOT ENLARGED
CAROTID PULSATION	NORMAL
TEMPERATURE	NORMAL
PULSE	97 / MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT
RESPIRATORY RATE	NORMAL

CARDIOVASCULAR SYSTEM	
BP	

BP	116/75	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	NORMAL	
MURMURS	ABSENT	

. .

Page 19 Of 23



View Details



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Fmail : wellness eastdelbi@srL in Email : wellness.eastdelhi@srl.in



PATIENT NAME : KUMARI SALONI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0028WF000247 PATIENT ID : KUMAF01019028 CLIENT PATIENT ID : ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status Preliminary	Results Biological	Reference Interval Units

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST	NORMAL
MOVEMENTS OF CHEST	SYMMETRICAL
BREATH SOUNDS INTENSITY	NORMAL
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)
ADDED SOUNDS	ABSENT

PER ABDOMEN

APPEARANCE	NORMAL
VENOUS PROMINENCE	ABSENT
LIVER	NOT PALPABLE
SPLEEN	NOT PALPABLE

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS	NORMAL
CRANIAL NERVES	NORMAL
CEREBELLAR FUNCTIONS	NORMAL
SENSORY SYSTEM	NORMAL
MOTOR SYSTEM	NORMAL
REFLEXES	NORMAL

MUSCULOSKELETAL SYSTEM

SPINE	NORMAL
JOINTS	NORMAL

. .

Page 20 Of 23



View Details



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelbi@srLin Email : wellness.eastdelhi@srl.in



PATIENT NAME : KUMARI SALONI	REF. DOCTOR : S	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	i	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status Preliminary	Results Biological	Reference Interval Units

BASIC EYE EXAMINATION

CONJUNCTIVA	NORMAL
EYELIDS	NORMAL
EYE MOVEMENTS	NORMAL
CORNEA	NORMAL
DISTANT VISION RIGHT EYE WITHOUT GLASSES	NORMAL
DISTANT VISION LEFT EYE WITHOUT GLASSES	NORMAL
NEAR VISION RIGHT EYE WITHOUT GLASSES	NORMAL
NEAR VISION LEFT EYE WITHOUT GLASSES	NORMAL
COLOUR VISION	NORMAL

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL	NORMAL
TYMPANIC MEMBRANE	NORMAL
NOSE	NO ABNORMALITY DETECTED
SINUSES	NORMAL
THROAT	NO ABNORMALITY DETECTED
TONSILS	NOT ENLARGED

SUMMARY

RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS RELEVANT LAB INVESTIGATIONS RELEVANT NON PATHOLOGY DIAGNOSTICS **REMARKS / RECOMMENDATIONS**

NOT SIGNIFICANT NOT SIGNIFICANT BACTERIURIA NO ABNORMALITIES DETECTED PLEASE CORELATE CLINICALLY

Page 21 Of 23



View Details



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Sensor Staginostes Leaving Email : wellness.eastdelhi@srl.in



PATIENT NAME : KUMARI SALONI	REF. DOCTOR :	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAL MEHRAULISOUTH WEST	ACCESSION NO : 0028WF000247 PATIENT ID : KUMAF01019028 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

Page 22 Of 23



View Details View Report



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

•

.



PATIENT NAME : KUMARI SALONI	REF. DOCTOR :	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0028WF000247 ΡΑΠΕΝΤ ID : KUMAF01019028 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :10/06/2023 09:38:18 REPORTED :12/06/2023 10:30:48
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

HEPATOMEGALY WITH IUCD SEEN IN SITU.

Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING		
 It is presumed that the test sample belongs to the patient named or identified in the test requisition form. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event. A requested test might not be performed if: Specimen quality is unsatisfactory iii. Incorrect specimen type iv. Discrepancy between identification on specimen container label and test requisition form 	 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity. 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis. 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification. 8. Test results cannot be used for Medico legal purposes. 9. In case of queries please call customer care (91115 91115) within 48 hours of the report. 	
	Agilus Diagnostics Limited	

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Page 23 Of 23



View Details



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar, Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in